vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $44.9M, roughly 1.1× AbCellera Biologics Inc.). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -19.9%, a 15.2% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -20.2%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
ABCL vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $47.7M |
| Net Profit | $-8.9M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | 14.3% |
| Net Margin | -19.9% | -4.8% |
| Revenue YoY | 788.4% | -47.3% |
| Net Profit YoY | 73.9% | -200.9% |
| EPS (diluted) | $-0.03 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $47.7M | ||
| Q3 25 | $9.0M | $122.1M | ||
| Q2 25 | $17.1M | $85.2M | ||
| Q1 25 | $4.2M | $41.1M | ||
| Q4 24 | $5.0M | $90.5M | ||
| Q3 24 | $6.5M | $91.6M | ||
| Q2 24 | $7.3M | $94.4M | ||
| Q1 24 | $10.0M | $74.9M |
| Q4 25 | $-8.9M | $-2.3M | ||
| Q3 25 | $-57.1M | $40.1M | ||
| Q2 25 | $-34.7M | $23.6M | ||
| Q1 25 | $-45.6M | $-37.4M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | $-51.1M | $3.6M | ||
| Q2 24 | $-36.9M | $-860.0K | ||
| Q1 24 | $-40.6M | $-4.2M |
| Q4 25 | -63.7% | 14.3% | ||
| Q3 25 | -851.8% | 61.8% | ||
| Q2 25 | -290.2% | 53.2% | ||
| Q1 25 | -1479.6% | -70.7% | ||
| Q4 24 | — | 34.8% | ||
| Q3 24 | -1439.4% | 28.0% | ||
| Q2 24 | -1276.2% | 26.5% | ||
| Q1 24 | -551.5% | 14.7% |
| Q4 25 | -19.9% | -4.8% | ||
| Q3 25 | -637.8% | 32.8% | ||
| Q2 25 | -203.3% | 27.7% | ||
| Q1 25 | -1077.2% | -90.9% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | -785.4% | 4.0% | ||
| Q2 24 | -504.3% | -0.9% | ||
| Q1 24 | -408.0% | -5.6% |
| Q4 25 | $-0.03 | $0.01 | ||
| Q3 25 | $-0.19 | $0.23 | ||
| Q2 25 | $-0.12 | $0.14 | ||
| Q1 25 | $-0.15 | $-0.23 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | $-0.17 | $0.02 | ||
| Q2 24 | $-0.13 | $-0.01 | ||
| Q1 24 | $-0.14 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $-261.8M |
| Total Assets | $1.4B | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $215.5M | ||
| Q3 25 | $83.2M | $140.4M | ||
| Q2 25 | $92.4M | $92.9M | ||
| Q1 25 | $159.3M | $108.5M | ||
| Q4 24 | $156.3M | $88.6M | ||
| Q3 24 | $126.6M | $88.2M | ||
| Q2 24 | $148.3M | $105.5M | ||
| Q1 24 | $123.6M | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | $966.9M | $-261.8M | ||
| Q3 25 | $964.0M | $-264.2M | ||
| Q2 25 | $1.0B | $-308.2M | ||
| Q1 25 | $1.0B | $-334.1M | ||
| Q4 24 | $1.1B | $-301.3M | ||
| Q3 24 | $1.1B | $-311.3M | ||
| Q2 24 | $1.1B | $-321.7M | ||
| Q1 24 | $1.1B | $-330.5M |
| Q4 25 | $1.4B | $396.9M | ||
| Q3 25 | $1.4B | $396.1M | ||
| Q2 25 | $1.4B | $342.9M | ||
| Q1 25 | $1.3B | $327.2M | ||
| Q4 24 | $1.4B | $350.9M | ||
| Q3 24 | $1.4B | $389.5M | ||
| Q2 24 | $1.4B | $395.6M | ||
| Q1 24 | $1.5B | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $74.6M |
| Free Cash FlowOCF − Capex | $-44.6M | $74.6M |
| FCF MarginFCF / Revenue | -99.4% | 156.3% |
| Capex IntensityCapex / Revenue | 21.9% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $74.6M | ||
| Q3 25 | $-52.6M | $47.6M | ||
| Q2 25 | $-32.4M | $-15.1M | ||
| Q1 25 | $-11.6M | $20.0M | ||
| Q4 24 | $-108.6M | $15.2M | ||
| Q3 24 | $-28.9M | $9.9M | ||
| Q2 24 | $-30.0M | $33.5M | ||
| Q1 24 | $-41.7M | $45.0M |
| Q4 25 | $-44.6M | $74.6M | ||
| Q3 25 | $-61.5M | $47.6M | ||
| Q2 25 | $-45.8M | $-15.1M | ||
| Q1 25 | $-22.2M | $19.9M | ||
| Q4 24 | $-187.0M | — | ||
| Q3 24 | $-47.4M | $9.9M | ||
| Q2 24 | $-50.1M | $33.4M | ||
| Q1 24 | $-65.8M | $44.9M |
| Q4 25 | -99.4% | 156.3% | ||
| Q3 25 | -687.0% | 39.0% | ||
| Q2 25 | -267.9% | -17.7% | ||
| Q1 25 | -524.0% | 48.4% | ||
| Q4 24 | -3702.8% | — | ||
| Q3 24 | -728.4% | 10.8% | ||
| Q2 24 | -683.8% | 35.4% | ||
| Q1 24 | -661.5% | 60.0% |
| Q4 25 | 21.9% | 0.0% | ||
| Q3 25 | 99.7% | 0.0% | ||
| Q2 25 | 78.2% | 0.0% | ||
| Q1 25 | 251.1% | 0.1% | ||
| Q4 24 | 1552.7% | 0.0% | ||
| Q3 24 | 284.6% | 0.0% | ||
| Q2 24 | 274.6% | 0.1% | ||
| Q1 24 | 242.5% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | — | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
